Cargando…

1.5T MR-Guided Daily-Adaptive SBRT for Prostate Cancer: Preliminary Report of Toxicity and Quality of Life of the First 100 Patients

Purpose: The present study reports the preliminary outcomes in terms of adverse events and quality of life in the first 100 patients treated with 1.5T MR-guided daily-adaptive stereotactic body radiotherapy for prostate cancer. Methods: From October 2019 to December 2020, 100 patients, enrolled in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Alongi, Filippo, Rigo, Michele, Figlia, Vanessa, Nicosia, Luca, Mazzola, Rosario, Giaj Levra, Niccolò, Ricchetti, Francesco, Trapani, Giovanna, Attinà, Giorgio, Vitale, Claudio, Pastorello, Edoardo, De Simone, Antonio, Gurrera, Davide, Naccarato, Stefania, Sicignano, Gianluisa, Ruggieri, Ruggero, Cuccia, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785799/
https://www.ncbi.nlm.nih.gov/pubmed/36556203
http://dx.doi.org/10.3390/jpm12121982
_version_ 1784858136630263808
author Alongi, Filippo
Rigo, Michele
Figlia, Vanessa
Nicosia, Luca
Mazzola, Rosario
Giaj Levra, Niccolò
Ricchetti, Francesco
Trapani, Giovanna
Attinà, Giorgio
Vitale, Claudio
Pastorello, Edoardo
De Simone, Antonio
Gurrera, Davide
Naccarato, Stefania
Sicignano, Gianluisa
Ruggieri, Ruggero
Cuccia, Francesco
author_facet Alongi, Filippo
Rigo, Michele
Figlia, Vanessa
Nicosia, Luca
Mazzola, Rosario
Giaj Levra, Niccolò
Ricchetti, Francesco
Trapani, Giovanna
Attinà, Giorgio
Vitale, Claudio
Pastorello, Edoardo
De Simone, Antonio
Gurrera, Davide
Naccarato, Stefania
Sicignano, Gianluisa
Ruggieri, Ruggero
Cuccia, Francesco
author_sort Alongi, Filippo
collection PubMed
description Purpose: The present study reports the preliminary outcomes in terms of adverse events and quality of life in the first 100 patients treated with 1.5T MR-guided daily-adaptive stereotactic body radiotherapy for prostate cancer. Methods: From October 2019 to December 2020, 100 patients, enrolled in a prospective study, received MR-guided SBRT for prostate cancer. Rectal spacer insertion was optional and administered in 37 patients. In total, 32 patients received androgen deprivation therapy in accordance with international guidelines. A prospective collection of data regarding toxicity and quality of life was performed. Results: The median age was 71 years (range, 52–84). The median total dose delivered was 35 Gy (35–36.25 Gy) in five sessions, either on alternate days (n = 25) or consecutive days (n = 75). For acute toxicity, we recorded: seven cases of acute G2 urinary pain and four cases of G2 gastrointestinal events. The median follow-up was 12 months (3–20), recording three late G2 urinary events and one G3 case, consisting of a patient who required a TURP 8 months after the treatment. For gastrointestinal toxicity, we observed 3 G ≥ 2 GI events, including one patient who received argon laser therapy for radiation-induced proctitis. Up to the last follow-up, all patients are alive and with no evidence of biochemical relapse, except for an M1 low-volume patient in distant progression two months after radiotherapy. QoL evaluation reported a substantial resolution of any discomfort within the second follow-up after radiotherapy, with the only exception being sexual items. Notably, after one year, global health items were improved compared to the baseline assessment. Conclusions: This study reports very promising outcomes in terms of adverse events and QoL, supporting the role of 1.5T MR-guided SBRT for prostate cancer. To date, this series is one of the first and largest available in the literature. Long-term results are warranted.
format Online
Article
Text
id pubmed-9785799
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97857992022-12-24 1.5T MR-Guided Daily-Adaptive SBRT for Prostate Cancer: Preliminary Report of Toxicity and Quality of Life of the First 100 Patients Alongi, Filippo Rigo, Michele Figlia, Vanessa Nicosia, Luca Mazzola, Rosario Giaj Levra, Niccolò Ricchetti, Francesco Trapani, Giovanna Attinà, Giorgio Vitale, Claudio Pastorello, Edoardo De Simone, Antonio Gurrera, Davide Naccarato, Stefania Sicignano, Gianluisa Ruggieri, Ruggero Cuccia, Francesco J Pers Med Article Purpose: The present study reports the preliminary outcomes in terms of adverse events and quality of life in the first 100 patients treated with 1.5T MR-guided daily-adaptive stereotactic body radiotherapy for prostate cancer. Methods: From October 2019 to December 2020, 100 patients, enrolled in a prospective study, received MR-guided SBRT for prostate cancer. Rectal spacer insertion was optional and administered in 37 patients. In total, 32 patients received androgen deprivation therapy in accordance with international guidelines. A prospective collection of data regarding toxicity and quality of life was performed. Results: The median age was 71 years (range, 52–84). The median total dose delivered was 35 Gy (35–36.25 Gy) in five sessions, either on alternate days (n = 25) or consecutive days (n = 75). For acute toxicity, we recorded: seven cases of acute G2 urinary pain and four cases of G2 gastrointestinal events. The median follow-up was 12 months (3–20), recording three late G2 urinary events and one G3 case, consisting of a patient who required a TURP 8 months after the treatment. For gastrointestinal toxicity, we observed 3 G ≥ 2 GI events, including one patient who received argon laser therapy for radiation-induced proctitis. Up to the last follow-up, all patients are alive and with no evidence of biochemical relapse, except for an M1 low-volume patient in distant progression two months after radiotherapy. QoL evaluation reported a substantial resolution of any discomfort within the second follow-up after radiotherapy, with the only exception being sexual items. Notably, after one year, global health items were improved compared to the baseline assessment. Conclusions: This study reports very promising outcomes in terms of adverse events and QoL, supporting the role of 1.5T MR-guided SBRT for prostate cancer. To date, this series is one of the first and largest available in the literature. Long-term results are warranted. MDPI 2022-11-30 /pmc/articles/PMC9785799/ /pubmed/36556203 http://dx.doi.org/10.3390/jpm12121982 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Alongi, Filippo
Rigo, Michele
Figlia, Vanessa
Nicosia, Luca
Mazzola, Rosario
Giaj Levra, Niccolò
Ricchetti, Francesco
Trapani, Giovanna
Attinà, Giorgio
Vitale, Claudio
Pastorello, Edoardo
De Simone, Antonio
Gurrera, Davide
Naccarato, Stefania
Sicignano, Gianluisa
Ruggieri, Ruggero
Cuccia, Francesco
1.5T MR-Guided Daily-Adaptive SBRT for Prostate Cancer: Preliminary Report of Toxicity and Quality of Life of the First 100 Patients
title 1.5T MR-Guided Daily-Adaptive SBRT for Prostate Cancer: Preliminary Report of Toxicity and Quality of Life of the First 100 Patients
title_full 1.5T MR-Guided Daily-Adaptive SBRT for Prostate Cancer: Preliminary Report of Toxicity and Quality of Life of the First 100 Patients
title_fullStr 1.5T MR-Guided Daily-Adaptive SBRT for Prostate Cancer: Preliminary Report of Toxicity and Quality of Life of the First 100 Patients
title_full_unstemmed 1.5T MR-Guided Daily-Adaptive SBRT for Prostate Cancer: Preliminary Report of Toxicity and Quality of Life of the First 100 Patients
title_short 1.5T MR-Guided Daily-Adaptive SBRT for Prostate Cancer: Preliminary Report of Toxicity and Quality of Life of the First 100 Patients
title_sort 1.5t mr-guided daily-adaptive sbrt for prostate cancer: preliminary report of toxicity and quality of life of the first 100 patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785799/
https://www.ncbi.nlm.nih.gov/pubmed/36556203
http://dx.doi.org/10.3390/jpm12121982
work_keys_str_mv AT alongifilippo 15tmrguideddailyadaptivesbrtforprostatecancerpreliminaryreportoftoxicityandqualityoflifeofthefirst100patients
AT rigomichele 15tmrguideddailyadaptivesbrtforprostatecancerpreliminaryreportoftoxicityandqualityoflifeofthefirst100patients
AT figliavanessa 15tmrguideddailyadaptivesbrtforprostatecancerpreliminaryreportoftoxicityandqualityoflifeofthefirst100patients
AT nicosialuca 15tmrguideddailyadaptivesbrtforprostatecancerpreliminaryreportoftoxicityandqualityoflifeofthefirst100patients
AT mazzolarosario 15tmrguideddailyadaptivesbrtforprostatecancerpreliminaryreportoftoxicityandqualityoflifeofthefirst100patients
AT giajlevraniccolo 15tmrguideddailyadaptivesbrtforprostatecancerpreliminaryreportoftoxicityandqualityoflifeofthefirst100patients
AT ricchettifrancesco 15tmrguideddailyadaptivesbrtforprostatecancerpreliminaryreportoftoxicityandqualityoflifeofthefirst100patients
AT trapanigiovanna 15tmrguideddailyadaptivesbrtforprostatecancerpreliminaryreportoftoxicityandqualityoflifeofthefirst100patients
AT attinagiorgio 15tmrguideddailyadaptivesbrtforprostatecancerpreliminaryreportoftoxicityandqualityoflifeofthefirst100patients
AT vitaleclaudio 15tmrguideddailyadaptivesbrtforprostatecancerpreliminaryreportoftoxicityandqualityoflifeofthefirst100patients
AT pastorelloedoardo 15tmrguideddailyadaptivesbrtforprostatecancerpreliminaryreportoftoxicityandqualityoflifeofthefirst100patients
AT desimoneantonio 15tmrguideddailyadaptivesbrtforprostatecancerpreliminaryreportoftoxicityandqualityoflifeofthefirst100patients
AT gurreradavide 15tmrguideddailyadaptivesbrtforprostatecancerpreliminaryreportoftoxicityandqualityoflifeofthefirst100patients
AT naccaratostefania 15tmrguideddailyadaptivesbrtforprostatecancerpreliminaryreportoftoxicityandqualityoflifeofthefirst100patients
AT sicignanogianluisa 15tmrguideddailyadaptivesbrtforprostatecancerpreliminaryreportoftoxicityandqualityoflifeofthefirst100patients
AT ruggieriruggero 15tmrguideddailyadaptivesbrtforprostatecancerpreliminaryreportoftoxicityandqualityoflifeofthefirst100patients
AT cucciafrancesco 15tmrguideddailyadaptivesbrtforprostatecancerpreliminaryreportoftoxicityandqualityoflifeofthefirst100patients